Katz Matthew H, Bouvet Michael
Department of Surgery, University of California at San Diego, San Diego, CA 92103, USA.
Int J Gastrointest Cancer. 2003;33(1):89-97. doi: 10.1385/IJGC:33:1:89.
One of the most lethal human malignancies, pancreatic adenocarcinoma has remained a therapeutic challenge. Historically, the only curable treatment modalities available to patients with this disease have included pancreaticoduodenectomy with adjuvant chemoradiation. Few patients, however, have resectable disease at the time of presentation, and even for those who are offered this radical course of treatment, post-surgical survival is dismally short. Recently, however, advances in the understanding of the molecular biology of pancreatic cancer have enabled researchers to investigate novel gene therapy approaches to the treatment of this disease. In this paper, we review the common genetic mutations found in pancreatic adenocarcinomas, discuss strategies for the manipulation of genetic targets, and assess current progress in the field of gene therapy as it relates to pancreatic cancer.
胰腺腺癌是最致命的人类恶性肿瘤之一，一直是治疗上的挑战。从历史上看，这种疾病患者唯一可治愈的治疗方式包括胰十二指肠切除术及辅助放化疗。然而，很少有患者在就诊时患有可切除的疾病，即使是那些接受这种根治性治疗方案的患者，术后生存期也极短。然而，最近对胰腺癌分子生物学认识的进展使研究人员能够研究治疗这种疾病的新型基因治疗方法。在本文中，我们综述了胰腺腺癌中常见的基因突变，讨论了操纵基因靶点的策略，并评估了与胰腺癌相关的基因治疗领域的当前进展。
